1189331-55-2

Upstream product

• 1189331-54-1 N-tert-butoxycarbonyl-1,4-dideoxy-2,3-O-isopropylidene-5-O-benzyl-1,4-imino-D-ribitol 
• 3969-61-7 2,3:5,6-di-O-isopropylidene-D-gulitol 
• 117859-45-7 methanesulfonic acid (S)-((4R)-2,2-dimethyl-[1,3]dioxolan-4-yl)-((4S,5S)-5-methanesulfonyloxymethyl-2,2-dimethyl-[1,3]dioxolan-4-yl)-methyl ester 
• 67642-42-6 2,3,5,6-di-O-isopropylidene-D-gulono-1,4-lactone 
• 22430-23-5 L-mannono-1,4-lactone 
• 152785-75-6 (3aS,4S,6aR)-tert-butyl 4-(hydroxymethyl)-2,2-dimethyldihydro-3aH-[1,3]dioxolo[4,5-c]pyrrole-5(4H)-carboxylate 

Relevant academic research and scientific papers

Anti-cancer activity of 5-O-alkyl 1,4-imino-1,4-dideoxyribitols

New derivatives of 1,4-dideoxy-1,4-imino-d-ribitol have been prepared and evaluated for their cytotoxicity on solid and haematological malignancies. 1,4-Dideoxy-5-O-[(9Z)-octadec-9-en-1-yl]-1,4-imino-d-ribitol (13, IC 50 ～2 μM) and its C18

NOVEL DIHYDROXYPYRROLIDINE DERIVATIVES AS ANTI-CANCER AGENTS

The present invention provides new dihydroxypyrrolidine derivatives for use as medicaments. The compounds are useful in the treatment in cancer, in particular non-solid neoplasms.